A post-marketing surveillance study of the safety and efficiacy of ReFacto® (Moroctocog Alfa, B-Domain deleted recombinant factor VIII) St. Louis-derived active substance in the treatment and prevension of bleeding episodes in hemophilia A patients.

被引：0
|
作者：
Feingold, JM
Smith, MP
Littlewood, R
Giangrande, P
机构：
[1] Wyeth Pharmaceut, Global Med Affairs, Collegeville, PA USA
[2] Canterbury Hlth Labs, Christchurch, New Zealand
[3] Wyeth Pharmaceut, Collegeville, PA USA
[4] Churchill Hosp, Oxford Haemophilia Ctr & Thrombosis Unit, Oxford OX3 7LJ, England
[5] Wyeth Pharmaceut, Collegeville, PA USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3101.5
引用
收藏
页码：847A / 848A
页数：2
相关论文
共 3 条
  • [1] Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study
    Kim, Soon Ki
    Yoo, Ki Young
    Lee, Kun Soo
    Hwang, Taiju
    Choi, Yong Mook
    Choi, Eun Jin
    Park, Sang Kyu
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2018, 33 (01)
  • [2] SAFETY AND EFFICACY OF B-DOMAIN DELETED 3RD GENERATION RECOMBINANT FACTOR VIII (GREENGENE FTM) IN KOREAN PATIENTS WITH HAEMOPHILIA A: DATA FROM A POST-MARKETING SURVEILLANCE STUDY
    Kim, S. K.
    Park, S. K.
    You, K. Y.
    Hwang, T. J.
    Choi, Y. M.
    HAEMATOLOGICA, 2016, 101 : 410 - 410
  • [3] Evaluation of the safety and efficacy of recombinant Factor IX (nonacog alfa) in Japanese patients with hemophilia B - The second interim analysis of 304 patients in a post-marketing surveillance study
    Amano, Kagehiro
    Fukutake, Katsuyuki
    Hanabusa, Hideji
    Taki, Masashi
    Matsushita, Tadashi
    Shima, Midori
    Sakai, Michio
    Yamaguchi, Hiromi
    Karumori, Toshiyuki
    HAEMOPHILIA, 2014, 20 : 22 - 22
1